Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 7;28(9):804-811.
doi: 10.1093/oncolo/oyad172.

Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration

Amanda M Moore  1   2 , Zohra Nooruddin  2 , Kelly R Reveles  1   2   3 , Jim M Koeller  1   2 , Jennifer M Whitehead  2   3 , Kathleen Franklin  3 , Paromita Datta  2   3 , Munaf Alkadimi  2   3 , Lance Brannman  4 , Ion Cotarla  5 , Andrew J Frankart  6 , Tiernan Mulrooney  5 , Xavier Jones  1   3 , Christopher R Frei  1   2   3
Affiliations

Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration

Amanda M Moore et al. Oncologist. .

Abstract

Background: Real-world evidence is limited regarding the relationship between race and use of durvalumab, an immunotherapy approved for use in adults with unresectable stage III non-small cell lung cancer (NSCLC) post-chemoradiotherapy (CRT). This study aimed to evaluate if durvalumab treatment patterns differed by race in patients with unresectable stage III NSCLC in a Veterans Health Administration (VHA) population.

Materials and methods: This was a retrospective analysis of White and Black adults with unresectable stage III NSCLC treated with durvalumab presenting to any VHA facility in the US from January 1, 2017, to June 30, 2020. Data captured included baseline characteristics and durvalumab treatment patterns, including treatment initiation delay (TID), interruption (TI), and discontinuation (TD); defined as CRT completion to durvalumab initiation greater than 42 days, greater than 28 days between durvalumab infusions, and more than 28 days from the last durvalumab dose with no new durvalumab restarts, respectively. The number of doses, duration of therapy, and adverse events were also collected.

Results: A total of 924 patients were included in this study (White = 726; Black = 198). Race was not a significant factor in a multivariate logistic regression model for TID (OR, 1.39; 95% CI, 0.81-2.37), TI (OR, 1.58; 95% CI, 0.90-2.76), or TD (OR, 0.84; 95% CI, 0.50-1.38). There were also no significant differences in median (interquartile range [IQR]) number of doses (White: 15 [7-24], Black: 18 [7-25]; P = .25) or median (IQR) duration of therapy (White: 8.7 months [2.9-11.8], Black: 9.8 months [3.6-12.0]; P = .08), although Black patients were less likely to experience an immune-related adverse event (28% vs. 36%, P = .03) and less likely to experience pneumonitis (7% vs. 14%, P < .01).

Conclusion: Race was not found to be linked with TID, TI, or TD in this real-world study of patients with unresectable stage III NSCLC treated with durvalumab at the VHA.

Keywords: durvalumab; health disparity; health equity; immunotherapy; lung cancer.

PubMed Disclaimer

Conflict of interest statement

The institutions of Christopher R. Frei, Zohra Nooruddin, Kelly R. Reveles, and Xavier Jones have received grant money, for them to perform research, from AstraZeneca, in the last three years. Lance Brannman, Ion Cotarla, and Tiernan Mulrooney are employees of AstraZeneca Pharmaceuticals. Andrew Frankart was supported by the ASTRO-AstraZeneca Radiation Oncology Research Training Fellowship. The other authors indicated no financial relationships.

Figures

Figure 1.
Figure 1.
Multivariable logistic regression analysis of risk factors for TID, TI, and TD. TID, treatment initiation delay; TI, treatment interruption; TD, treatment discontinuation; CI, confidence interval.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Antonia SJ, Villegas A, Daniel D, et al. ; PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929. 10.1056/NEJMoa1709937. - DOI - PubMed
    1. Guerrero S, Lopez-Cortes A, Indacochea A, et al. . Analysis of racial/ethnic representation in select basic and applied cancer research studies. Sci Rep. 2018;8(1):13978. 10.1038/s41598-018-32264-x. - DOI - PMC - PubMed
    1. Kwiatkowski K, Coe K, Bailar JC, Swanson GM.. Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved? Cancer. 2013;119(16):2956-2963. 10.1002/cncr.28168. - DOI - PubMed
    1. Nazha B, Mishra M, Pentz R, Owonikoko TK.. Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy. Am Soc Clin Oncol Educ Book. 2019;39(May 17):3-10. 10.1200/EDBK_100021. - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A.. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. 10.3322/caac.21590. - DOI - PubMed

Publication types